RedShift BioAnalytics Closes $20M Series E Funding Led by Illumina Ventures

BURLINGTON, Mass.–(BUSINESS WIRE)–RedShift BioAnalytics Inc. (RedShiftBio), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, announced today the closing of its Series…

Click here to view the original article.